Should we treat every infant with a probiotic?

Research output: Contribution to journalArticle

Abstract

Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of probiotics in infantile colic is strong but limited to the L. reuteri DSM 17938 strain and to breast-fed infants. The evidence for prevention of atopic dermatitis is mixed with the strongest benefit seen with initiation of probiotic treatment during pregnancy and continued after birth. The more provocative question of whether routine administration of probiotics to all infants can reverse trends in intestinal dysbiosis and dysbiosis-associated diseases remains unanswered. A large cohort study or randomized controlled trial of probiotics in infancy with sufficient follow-up to assess changes in dysbiosis-associated diseases is warranted and could be paradigm shifting.

Original languageEnglish (US)
Pages (from-to)253-262
Number of pages10
JournalMinerva pediatrica
Volume71
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Dysbiosis
Probiotics
Necrotizing Enterocolitis
Sanitation
Colic
Atopic Dermatitis
Developed Countries
Premature Infants
Cesarean Section
Sepsis
Breast
Chronic Disease
Cohort Studies
Randomized Controlled Trials
Parturition
Anti-Bacterial Agents
Pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Should we treat every infant with a probiotic? / Underwood, Mark.

In: Minerva pediatrica, Vol. 71, No. 3, 01.06.2019, p. 253-262.

Research output: Contribution to journalArticle

@article{311d91afc62e4aa5b1387ee2b0535c2e,
title = "Should we treat every infant with a probiotic?",
abstract = "Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of probiotics in infantile colic is strong but limited to the L. reuteri DSM 17938 strain and to breast-fed infants. The evidence for prevention of atopic dermatitis is mixed with the strongest benefit seen with initiation of probiotic treatment during pregnancy and continued after birth. The more provocative question of whether routine administration of probiotics to all infants can reverse trends in intestinal dysbiosis and dysbiosis-associated diseases remains unanswered. A large cohort study or randomized controlled trial of probiotics in infancy with sufficient follow-up to assess changes in dysbiosis-associated diseases is warranted and could be paradigm shifting.",
author = "Mark Underwood",
year = "2019",
month = "6",
day = "1",
doi = "10.23736/S0026-4946.19.05526-9",
language = "English (US)",
volume = "71",
pages = "253--262",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Should we treat every infant with a probiotic?

AU - Underwood, Mark

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of probiotics in infantile colic is strong but limited to the L. reuteri DSM 17938 strain and to breast-fed infants. The evidence for prevention of atopic dermatitis is mixed with the strongest benefit seen with initiation of probiotic treatment during pregnancy and continued after birth. The more provocative question of whether routine administration of probiotics to all infants can reverse trends in intestinal dysbiosis and dysbiosis-associated diseases remains unanswered. A large cohort study or randomized controlled trial of probiotics in infancy with sufficient follow-up to assess changes in dysbiosis-associated diseases is warranted and could be paradigm shifting.

AB - Intestinal dysbiosis is associated with a long list of both acute and chronic inflammatory diseases and appears to be increasing in developed countries over the last century with the introduction of antibiotics, changes in sanitation, formula feeding and cesarean sections. The evidence supporting prophylactic administration of probiotic microbes to very preterm infants for the prevention of necrotizing enterocolitis, late onset sepsis and death is strong. The evidence for benefit of probiotics in infantile colic is strong but limited to the L. reuteri DSM 17938 strain and to breast-fed infants. The evidence for prevention of atopic dermatitis is mixed with the strongest benefit seen with initiation of probiotic treatment during pregnancy and continued after birth. The more provocative question of whether routine administration of probiotics to all infants can reverse trends in intestinal dysbiosis and dysbiosis-associated diseases remains unanswered. A large cohort study or randomized controlled trial of probiotics in infancy with sufficient follow-up to assess changes in dysbiosis-associated diseases is warranted and could be paradigm shifting.

UR - http://www.scopus.com/inward/record.url?scp=85065287022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065287022&partnerID=8YFLogxK

U2 - 10.23736/S0026-4946.19.05526-9

DO - 10.23736/S0026-4946.19.05526-9

M3 - Article

C2 - 31017382

AN - SCOPUS:85065287022

VL - 71

SP - 253

EP - 262

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

IS - 3

ER -